Outlook Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $67.41M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Dec 18, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | $9.00K | $0.15 | $0.09 |
| Q2 FY2026 Ended Mar 31, 2026 | May 18, 2026 | After market close | $128.00K | $0.05 | $0.16 |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 17, 2026 | Before market open | -$1.21M | $-0.38 | $-0.22 |
| Q4 FY2025 Ended Sep 30, 2025 | Dec 19, 2025 | Before market open | – | – | – |
| Q3 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $1.50M | – | – |
| Q2 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | $1.50 | $0.40 |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 14, 2025 | Before market open | – | $0.72 | $-0.89 |
| Q4 FY2024 Ended Sep 30, 2024 | Dec 27, 2024 | Before market open | – | – | – |
| Q3 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-0.89 | $-0.83 |
| Q2 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Dec 31, 2023 | Feb 14, 2024 | After market close | – | – | – |
Press releases
Announcements Outlook Therapeutics filed with the SEC
Outlook Therapeutics Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
the risks and uncertainties described below. If any of the following risks are realized, our business, financial condition, results of
Results of operations · Other events · EX-99.1 to Form 8-K
Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Other events · EX-99.1 to Form 8-K
Announces FDA Acceptance of Resubmitted Biologics
Other events · EX-99.1 to Form 8-K
of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Other events · EX-99.1 to Form 8-K
Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Other events · EX-99.1 to Form 8-K
Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Other events · EX-99.1 to Form 8-K
Announces Formal Dispute Resolution Request for
Other events · EX-99.1 to Form 8-K
Except as set forth below, as of March 16, 2026,
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Outlook Therapeutics Provides Update Following
Other events · EX-99.1 to Form 8-K
Outlook Therapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics Submits Type A Meeting
Other events · EX-99.1 to Form 8-K
Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment
Other events · EX-99.1 to Form 8-K
Reports Financial Results for Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics Re-Submits Biologics License
Other events · EX-99.1 to Form 8-K
Provides Update on Type A Meeting with FDA
Other events · EX-99.1 to Form 8-K
Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for
Other events · EX-99.1 to Form 8-K
Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Topline Results of NORSE EIGHT Clinical Trial
Other events · EX-99.1 to Form 8-K
Therapeutics ® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics® Announces UK Submission
Other events · EX-99.1 to Form 8-K
Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics® Receives FDA Agreement
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics® Provides Update on
Other events · EX-99.1 to Form 8-K
Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Other events · EX-99.1 to Form 8-K
Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Results of operations · EX-99.1 to Form 8-K
Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Results for Fiscal Year 2022 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Outlook Therapeutics Announces $25 Million Registered
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
Other events · EX-99.1 to Form 8-K
Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K